)
Visual
test
Viking Therapeutics
Viking Therapeutics (VKTX) investor relations material
Viking Therapeutics Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary14 Jan, 2026
Strategic focus and pipeline
Focused on developing novel therapeutics for metabolic and endocrine diseases, with multiple clinical programs showing strong efficacy data.
Lead asset VK2735, a GLP-1/GIP dual agonist, is being developed in both injectable and oral forms for obesity, with Phase 3 and Phase 2 studies underway or completed.
Additional programs include an amylin agonist for obesity (IND planned 1Q26), VK2809 for MASH (successful Phase 2b), and VK0214 for X-ALD (successful Phase 1b).
VK2735 clinical results and efficacy
VK2735 demonstrated up to 14.7% mean weight loss after 13 weeks in Phase 2 subcutaneous studies, with dose-dependent effects and no plateau observed.
Oral VK2735 achieved up to 12.2% mean weight loss after 13 weeks, with progressive and durable effects maintained post-dosing.
Both formulations showed rapid, progressive weight loss, with significant differences from placebo at all time points for doses above 15 mg.
Exploratory maintenance cohorts suggest lower maintenance doses can sustain or extend weight loss.
Safety and tolerability
Majority of treatment-emergent adverse events (TEAEs) were mild to moderate, with GI-related events (nausea, vomiting, diarrhea, constipation) most common and generally subsiding over time.
Discontinuation rates were dose-dependent and mainly related to GI side effects, but most events resolved with titration.
Promising tolerability profile observed through high dose levels in both oral and injectable studies.
How does VK2735 PK profile compare to tirzepatide?
What is the expected timeline for oral maintenance data?
Assess the financial runway based on current burn rate.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6 FebSCW
73% revenue growth and record backlog driven by new space contracts and strategic investments. - 6 FebCDP
2025 FFO/share rose 5.8% with strong leasing and retention; 2026 guidance signals further growth. - 6 FebSCWRevenue at 15.86 mln PLN, backlog 17.14 mln PLN, and major space contracts drive 2025 outlook.
- 6 FebPENG
All proposals passed, with no questions raised during the Q&A session. - 6 FebSCWQ2 2024 revenue up 115% y/y, backlog nearly doubled, Space segment leads growth.
- 6 FebPECO
2026 FFO per share growth guided at 5.5% with record occupancy and strong acquisitions. - 6 FebISCTR
Net profit up 90% in 2025, with strong NIM, fee growth, and positive 2026 outlook. - 6 FebSCWQ2 2025 revenue surged 120% y/y, driven by a record Asian contract and a tripled backlog.
- 6 FebSCWQ1 2025 revenue jumped 97% year-over-year, with strong backlog and major new contracts secured.
- 6 FebSCWQ3 revenue up 39% y/y, backlog at 58.3 mln PLN, Space leads growth with global contracts.
Next Viking Therapeutics earnings date
Q4 202511 Feb, 2026
Viking Therapeutics
Next Viking Therapeutics earnings date
Q4 202511 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Viking Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders. The company utilizes small-molecule drug technology to target conditions such as liver diseases, muscle disorders, and other chronic illnesses. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage